Literature DB >> 3666481

The use of psychophysical, structural, and electrodiagnostic parameters to identify glaucomatous damage.

S M Drance1, P J Airaksinen, M Price, M Schulzer, G R Douglas, B Tansley.   

Abstract

Fifty-one patients with early glaucoma and 29 patients without the disease had their contrast sensitivity, colour vision, differential light threshold, neuroretinal rim area, retinal nerve fibre layer, pattern-reversal electrogram and visually evoked potential examined. A stepwise discriminant analysis found that the combination of the vertical cup disc ratio, the diffuse nerve fibre layer score and the localized nerve fibre layer score correctly identified 98% of the normals and 84% of the glaucoma patients. Single parameters and various combinations of parameters were also examined for their ability to discriminate between the two groups. Fifty-two glaucoma suspects were similarly examined and were classified into those whose discriminant functions were normal or abnormal.

Entities:  

Mesh:

Year:  1987        PMID: 3666481     DOI: 10.1007/bf02153407

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  Increased scatter of responses as a precursor of visual field changes in glaucoma.

Authors:  E B Werner; S M Drance
Journal:  Can J Ophthalmol       Date:  1977-04       Impact factor: 1.882

2.  Sector haemorrhage--a probable acute ischaemic disc change in chronic simple glaucoma.

Authors:  S M Drance; I S Begg
Journal:  Can J Ophthalmol       Date:  1970-04       Impact factor: 1.882

3.  Correlation between color vision scores and quantitative perimetry in suspected glaucoma.

Authors:  J Flammer; S M Drance
Journal:  Arch Ophthalmol       Date:  1984-01

4.  Diffuse and localized nerve fiber loss in glaucoma.

Authors:  P J Airaksinen; S M Drance; G R Douglas; D K Mawson; H Nieminen
Journal:  Am J Ophthalmol       Date:  1984-11       Impact factor: 5.258

5.  Acquired color vision changes in glaucoma. Use of 100-hue test and Pickford anomaloscope as predictors of glaucomatous field change.

Authors:  S M Drance; R Lakowski; M Schulzer; G R Douglas
Journal:  Arch Ophthalmol       Date:  1981-05

6.  Relative afferent pupillary defect in glaucoma.

Authors:  M B Kaback; R M Burde; B Becker
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

7.  Quantification of glaucomatous visual field defects with automated perimetry.

Authors:  J Flammer; S M Drance; L Augustiny; A Funkhouser
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-02       Impact factor: 4.799

8.  Early glaucoma changes in patients with and without an optic disc haemorrhage.

Authors:  P J Airaksinen; A Tuulonen
Journal:  Acta Ophthalmol (Copenh)       Date:  1984-04

9.  Neuroretinal rim area in suspected glaucoma and early chronic open-angle glaucoma. Correlation with parameters of visual function.

Authors:  A G Balazsi; S M Drance; M Schulzer; G R Douglas
Journal:  Arch Ophthalmol       Date:  1984-07

10.  Abnormalities of central contrast sensitivity in glaucoma.

Authors:  A Atkin; I Bodis-Wollner; M Wolkstein; A Moss; S M Podos
Journal:  Am J Ophthalmol       Date:  1979-08       Impact factor: 5.258

View more
  3 in total

1.  Correlation of spatial contrast sensitivity and visual fields in glaucoma.

Authors:  M Zulauf; J Flammer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

2.  Sequential classification in glaucoma diagnosis.

Authors:  Andrea Stroux; Peter Martus; Wido Budde; Folkert Horn; Anselm Jünemann; Matthias Korth; Jost B Jonas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-03-21       Impact factor: 3.117

3.  Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma.

Authors:  Dimitris Papaconstantinou; Ilias Georgalas; George Kalantzis; Efthimios Karmiris; Chrysanthi Koutsandrea; Andreas Diagourtas; Ioannis Ladas; Gerasimos Georgopoulos
Journal:  Clin Ophthalmol       Date:  2009-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.